Colorectal Cancer News and Research RSS Feed - Colorectal Cancer News and Research

Colorectal Cancer is cancer that develops in the colon (the longest part of the large intestine) and/or the rectum (the last several inches of the large intestine before the anus). In the United States, it is the fourth most common cancer in men and women. Caught early, it is often curable.
Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. [More]
Hormone loss may cause colon cancer, say Thomas Jefferson University researchers

Hormone loss may cause colon cancer, say Thomas Jefferson University researchers

Some cancers, like breast and prostate cancer, are driven by hormones such as estrogen and testosterone, but to date, there are none that are driven by the lack of a hormone. New evidence suggests that human colon cells may become cancerous when they lose the ability to produce a hormone that helps the cells maintain normal biology. If verified by further studies, it suggests that treating patients at high risk for colon cancer by replacing the hormone guanylin could prevent the development of cancer. [More]
NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

NCCN publishes 20th annual editions of NCCN Guidelines for Colon and Rectal Cancers

The National Comprehensive Cancer Network has published the 20th annual editions of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon and Rectal Cancers, two of the eight original NCCN Guidelines published in November 1996. [More]
VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

VolitionRx announces additional colorectal cancer data at International Conference of Anticancer Research

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests, today announced that further data analysis from its colorectal cancer study was presented today at the 9th International Conference of Anticancer Research, being held October 6-10, 2014 in Sithonia, Greece. [More]
University of Luxembourg researchers identify potential new ways to test colorectal cancer

University of Luxembourg researchers identify potential new ways to test colorectal cancer

Researchers at the University of Luxembourg have identified potential new ways to test for the first signs of one of the most deadly types of cancer: colorectal cancer. They have found new "biomarkers": molecules whose increased presence or absence in tissue suggests the development of tumorous cells. These indicators could help detect colorectal cancer at an early stage, predict its severity or even offer new treatments. [More]
Researchers generate fruit fly model, unveil key genetic factors behind human colon cancer

Researchers generate fruit fly model, unveil key genetic factors behind human colon cancer

Researchers at the Institute for Research in Biomedicine (IRB Barcelona) have managed to generate a fruit fly (Drosophila melanogaster) model that reproduces human colon cancer. With two publications appearing in PLoS One and EMBO Reports, the IRB team also unveil the function of a key gene in the development of the disease. [More]
Cancer Network presents exclusive coverage of ESMO 2014 Congress

Cancer Network presents exclusive coverage of ESMO 2014 Congress

UBM Medica US announces that Cancer Network, a leading online community for oncologists and others who treat cancer and the online home of the journal ONCOLOGY, presents exclusive coverage of the European Society for Medical Oncology (ESMO) 2014 Congress, held September 26–30 in Madrid, Spain. [More]
GenomOncology, med fusion partner to optimize treatment strategies for tumor

GenomOncology, med fusion partner to optimize treatment strategies for tumor

med fusion, an integrated molecular center of excellence and clinical trials service organization and GenomOncology, an Ohio based genomics technology and services provider, today announced a partnership to optimize treatment strategies based on the patient's disease state and tumor profile. [More]
Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Ferring Pharmaceuticals to introduce new cranberry flavor option of PREPOPIK in 2015

Colonoscopy is an important and widely used screening tool for colorectal cancer, but for many patients the bowel-preparation process is more uncomfortable than the procedure itself. To offer an alternative choice in bowel preparation, Ferring Pharmaceuticals Inc. will introduce a new cranberry flavor option of PREPOPIK in January 2015. [More]
Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

Dandrit Biotech A/S Signs Agreement To Commence Clinical Trials Of Melcancervac®

DanDrit Biotech A/S ("DanDrit Denmark"), the subsidiary of DanDrit Biotech USA, Inc. ("DanDrit"), a biotechnology company seeking to develop an approved vaccine for the treatment of colorectal cancer, signed a contract of collaboration with the University Hospital IRCCS "San Martino" - IST – National Institute for Cancer Research known as the San Martino Hospital of Genoa. [More]
Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. [More]
Retrospective study finds overuse of colonoscopies for colorectal cancer screening, surveillance

Retrospective study finds overuse of colonoscopies for colorectal cancer screening, surveillance

A retrospective study led by researchers at Brigham and Women's Hospital (BWH), has found an overuse of colonoscopies for colorectal cancer screening and surveillance. [More]
Survey: Many patients not always well informed about treatment options

Survey: Many patients not always well informed about treatment options

More than three quarters of oncology specialists in Europe, South America and Asia believe their patients are not always well enough informed about the treatment options available to them, survey results have revealed at the ESMO 2014 Congress in Madrid, Spain. [More]
Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

Lung-MAP, ALCHEMIST clinical trials offer innovative study designs for lung cancer patients

The recent launch of two clinical trials offer innovative study designs for patients with lung cancer. These clinical trials are the direct result of a National Cancer Institute sponsored workshop chaired by Drs. Fred R. Hirsch, Shakun Malik and Claudio Dansky- Ullman, that brought together the NCI Thoracic Malignancies Steering Committee, the US Food and Drug Administration, academicians, clinicians as well as industry and government stakeholders to discuss issues and challenges related to clinical trial design and biomarkers for lung cancer targeted-therapies. [More]
Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

Fecal occult blood screening increases diagnosis rate of high-risk polyps by 89%

The introduction of biennial colorectal cancer screening in a region of France increased the rate of diagnosis of high risk pre-cancerous adenomas (sometimes called polyps) by 89%, researchers have reported at the ESMO 2014 Congress in Madrid. [More]
NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib (BIBF 1120) in non-small cell lung, colorectal, and gastrointestinal cancers. [More]
Patients and healthcare professionals willing to trade false-positive diagnoses, study finds

Patients and healthcare professionals willing to trade false-positive diagnoses, study finds

Both patients and healthcare professionals believe diagnosis of extracolonic malignancy with screening computed tomography (CT) colonography greatly outweighs the potential disadvantages of subsequent radiologic or invasive follow-up tests precipitated by false-positive diagnoses, according to a new study published in the October issue of the journal Radiology. [More]
Promising new approach for combating colorectal cancer

Promising new approach for combating colorectal cancer

Scientists at the University of York are working on a promising new approach for tackling colorectal cancer, the second most common cause of cancer-related death. [More]

Propanc, Southridge Partners enter into equity purchase agreement

Propanc Health Group Corporation, an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA") with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the execution of its business plan, on favorable terms. [More]
Consensus statement on adequate bowel cleansing for colonoscopy

Consensus statement on adequate bowel cleansing for colonoscopy

The success of a colonoscopy is closely linked to good bowel preparation, with poor bowel prep often resulting in missed precancerous lesions, according to new consensus guidelines released by the U.S. Multi-Society Task force on Colorectal Cancer. [More]